Last reviewed · How we verify
TBE vaccine for adults
At a glance
| Generic name | TBE vaccine for adults |
|---|---|
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine (PHASE4)
- Primary TBE Vaccination for the Elderly (PHASE4)
- Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules (PHASE4)
- Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults (PHASE4)
- Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults (PHASE1)
- Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TBE vaccine for adults CI brief — competitive landscape report
- TBE vaccine for adults updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI